Compare CWH & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWH | SGMT |
|---|---|---|
| Founded | 1966 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.1M | 676.3M |
| IPO Year | 2016 | 2021 |
| Metric | CWH | SGMT |
|---|---|---|
| Price | $5.83 | $10.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $15.78 | ★ $26.13 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.99 | N/A |
| Revenue | ★ $4,792,017,000.00 | $2,000,000.00 |
| Revenue This Year | $4.63 | N/A |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $1.51 | ★ N/A |
| Revenue Growth | ★ 11.83 | N/A |
| 52 Week Low | $5.49 | $4.50 |
| 52 Week High | $18.22 | $11.45 |
| Indicator | CWH | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 61.77 |
| Support Level | $5.59 | $6.60 |
| Resistance Level | $6.95 | $11.15 |
| Average True Range (ATR) | 0.31 | 0.51 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 20.04 | 56.18 |
Camping World Holdings Inc is a retailer of RVs and related products and services. The company offers RV products and services with a national network of RV dealerships, service centers and customer support centers. It operates in two reportable segments: Good Sam Services and Plans; and RV and Outdoor Retail. The majority of the revenue is derived from RV and Outdoor Retail segment that derives revenue from the sale of new and used RVs; commissions on the finance and insurance contracts related to the sale of RVs; the sale of RV service and collision work; the sale of RV parts, accessories, and supplies; the sale of outdoor products, equipment, gear and supplies; and the sale of Good Sam Club memberships and co-branded credit cards.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.